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Duration of antibodiesIntroduction: We conducted a follow-on study to a phase I randomized, controlled trial conducted in
Cuba, 2012, to assess the persistence of poliovirus antibodies at 21–22 months following booster dose
of Sabin-IPV compared to Salk-IPV in adults who had received multiple doses of oral poliovirus vaccine
(OPV) during childhood.
Methods: In 2012, 60 healthy adult males aged 19–23 were randomized to receive one booster dose, of
either Sabin-inactivated poliovirus vaccine (Sabin-IPV), adjuvanted Sabin-IPV (aSabin-IPV), or conven-
tional Salk-IPV. In the original study, blood was collected at days 0 (before) and 28 (after vaccination),
respectively. In this study, an additional blood sample was collected 21–22 months after vaccination,
and tested for neutralizing antibodies to Sabin poliovirus types 1, 2 and 3.
Results: We collected sera from 59/60 (98.3%) subjects; 59/59 (100%) remained seropositive to all polio-
virus types, 21–22 months after vaccination. The decay curves were very similar among the study groups.
Between day 28 and 21–22 months, there was a reduction of P87.4% in median antibody levels for all
poliovirus types in all study groups, with no significant differences between the study groups.
Conclusion: The decay of poliovirus antibodies over a 21–22-month period was similar regardless of the
type of booster vaccine used, suggesting the scientific data of Salk IPV long-term persistence and decay
may be broadly applicable to Sabin IPV.
 2015 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
In 2008, the WHA recommended the WHO develop safer inacti-
vated poliovirus vaccine (IPV) production technology using attenu-
ated seed strains, such as Sabin polioviruses (Sabin-IPV) [1]. Sabin-
IPV technology would partly address the biosafety risks associated
with Sabin-IPV production, therefore allowing for production in
developing countries [2,3].
The immunogenicity of Sabin-IPV administered in the primary
series has been well-established in different clinical studies in
China, Japan, Poland, and Cuba [4–7], some of which demonstrated
that Sabin-IPV induced adequate neutralizing antibodies to both
Sabin and wild poliovirus [6,8]. Sabin-IPV products are currently
licensed in Japan and China, and are under development in manyother countries [9]. As Sabin-IPV and adjuvanted Sabin-IPV
(aSabin-IPV) are expected to be widely used in the near future, it
is important to assess the medium and long-term persistence of
Sabin-IPV boosted antibody response.
Several studies have demonstrated the long-term presence of
neutralizing antibodies, induced by Salk IPV [10–13]. To date how-
ever, only one study has assessed the duration of immunity
induced by Sabin-IPV. This was a phase III trial conducted in Japan,
using tetravalent diphtheria-tetanus-acellular pertussis-Sabin-IPV
vaccine (DTaP-Sabin-IPV), which demonstrated comparable immu-
nity between Salk-IPV and DTaP-Sabin-IPV, 6–18 months after vac-
cination [5].
We conducted a follow-on study to the phase I Cuba study con-
ducted in 2012. This study is the first to assess and compare the
decay of neutralizing antibodies to poliovirus, between day 28
and 21–22 months, in adults who received multiple doses of oral
poliovirus vaccine (OPV) during childhood, following a booster
dose of either Sabin-IPV, aSabin-IPV, or Salk-IPV, in a tropical
setting.
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In the phase I trial in Cuba conducted in 2012, sixty healthy
male subjects aged 19–23 years, who had received polio vaccina-
tion with multiple doses of OPV during childhood, in accordance
with the Cuban national immunisation program, and with no his-
tory of receiving poliovirus vaccine since the age of 9 years, were
enrolled and randomized, to receive a booster dose of either con-
ventional Salk-IPV, or Sabin-IPV, or aSabin-IPV (adjuvanted with
Aluminum hydroxide), with the following formulations: Salk-IPV
40:8:32 D-antigen Units per dose (DU/dose), Sabin-IPV 20:32:64
DU/dose, and aSabin-IPV 10:16:32 DU/dose and 0.5 mg aluminum
hydroxide, respectively [14]. All Sabin-IPV and Salk-IPV vaccines
were provided by the Netherlands Vaccine Institute (NVI) (cur-
rently called Intravacc) [7].
In our follow-on study, all subjects were contacted at 21–
22 months after initial vaccination, for blood collection. Sera were
tested at the Institute Pedro Kouri, for neutralizing antibodies to
Sabin poliovirus types 1–3, using standard micro-neutralization
assay. The antibody titers were diluted to 1:65,536, above the stan-
dard 1:1024 because high titers were expected with a boosting
dose of IPV. Seroconversion was defined as a Pfourfold increase
in reciprocal antibody titers.
We calculated the decay in antibody titers at day 28 and at 21–
22 months, and the overall increase in antibody titers during day 0
and 21–22 months, by poliovirus type and study arm with 95%
confidence intervals using bootstrapping sampling and estimation
with 10,000 replications. We tested differences in antibody titers
between the study groups, with Salk-IPV as the reference group,
by poliovirus type, using Wilcoxon rank sum test with significance
indicated by p 6 0.05. All analyses were conducted using statistical
application ‘‘R 3.1.2” [15].3. Results
3.1. Study population
In the previous study, there were no significant differences
between the three groups, in baseline characteristics of age, height,
weight, time since receiving last OPV dose, or, baseline titer of neu-
tralizing antibodies to Sabin poliovirus types 1–3 [7].Fig. 1. Median antibody titers (log2) to poliovirus types 1–3, on day 0, day 28, and 21–2
with 10,000 replications.In our study, a total of 59/60 (93.1%) subjects were followed-up
at 21–22 months (654–675 days). One subject in the aSabin-IPV
arm was lost to follow-up, and one subject in the aSabin-IPV group
had moved to Havana, where their blood was collected.3.2. Antibody decay (day 28 to 21–22 months)
In the previous study, there were no differences in immuno-
genicity to Sabin poliovirus types 1–3 between the study groups
during day 0 and day 28, with all subjects seroconverting or
boosted by day 28 [7]. At day 28, median antibody titers were
highest for poliovirus type 1 in the Sabin-IPV study group, and
for poliovirus types 2 and 3 in the aSabin-IPV group (Fig. 1).
In our study, at 21–22 months, all subjects had detectable
antibody titers for all Sabin poliovirus types, with median antibody
titers highest for poliovirus types 1 and 2 in the Sabin-IPV
study group, and for poliovirus type 3, in aSabin-IPV group. Median
titers were lowest for all poliovirus types in the Salk-IPV group.
We did not find any significant differences in median antibody
titers between the study groups for all poliovirus types (Fig. 1,
Table 1).
There were no statistically significant differences in the decay of
antibody titers during day 28 and 21–22 months, between Salk-
IPV, Sabin-IPV and aSabin-IPV groups, with relative reduction as
a percentage decline in median antibody titers by poliovirus type:
92.1%, 92.1%, 87.4% for poliovirus type 1 (p = 0.54; p = 0.61, respec-
tively); 96.0%, 95.0%, 95.0% for poliovirus type 2 (p = 0.66; p = 0.93,
respectively); 93.7%, 92.1%, 93.7% for poliovirus type 3 (p = 0.67;
p = 0.50, respectively) (Table 2).3.3. Antibody increase (day 0 to 21–22 months)
There were no statistically significant differences in the relative
increase in antibodies from day 0 to 21–22 months between Salk-
IPV, Sabin-IPV and aSabin-IPV study groups by poliovirus type:
1121.3%, 1028.5%, 893.0%, for poliovirus type 1 (p = 0.53; p = 0.40,
respectively); 458.7%, 694.7%, 402.8% for poliovirus type 2
(p = 0.71; p = 0.95, respectively); 320.5, 450.0, 566.0, for poliovirus
type 3 (p = 0.72; p = 0.54, respectively) (Table 2).2 months, by study group; 95% confidence intervals calculated using bootstrapping
Table 1
Median antibody titers (log2) to poliovirus types 1–3, on day 0, day 28, and 21–22 months, by study group with 95% confidence intervals calculated using bootstrapping with
10,000 replications.
Day 0 Day 28 21–22 months
Median titer (95% CI) p-Value Median titer (95% CI) p-Value Median titer (95% CI) p-Value
Type 1 Salk IPV 45.0 (18.0–71.0) Ref 3573.0 (2839.0–5664.0) Ref 450.0 (357.0–635.3) Ref
Sabin IPV 36.0 (25.4–100.8) 0.322 8053.0 (4009.4–11300.0) 0.271 508.0 (318.4–1007.3) 0.693
aSabin IPV 57.0 (14.0–142.0) 0.473 3573.0 (2255.0–5664.0) 0.365 450.0 (284.0–566.0) 0.64
Type 2 Salk IPV 51.0 (28.0–90.0) Ref 5664.0 (4009.4–8976.0) Ref 254.5 (179.0–400.8) Ref
Sabin IPV 57.0 (36.0–126.9) 0.957 7130.0 (5664.0–8976.0) 0.225 403.5 (318.4–566.0) 0.177
aSabin IPV 71.0 (36.0–113.0) 0.693 7130.0 (4499.0–11300.0) 0.365 357.0 (225.0–566.0) 0.352
Type 3 Salk IPV 25.5 (15.9–50.6) Ref 4036.0 (2009.7–10071.2) Ref 320.5 (225.0–504.7) Ref
Sabin IPV 25.5 (14.1–71.0) 0.755 4499.0 (3184.9–5664.0) 0.946 450.0 (225.0–635.3) 0.724
aSabin IPV 28.0 (14.0–57.0) 0.921 5664.0 (2839.0–14226.0) 0.248 566.0 (225.0–898.0) 0.535
Note: excluded 1 subject missing data for 21–22 months.
Table 2
Relative increase in median antibody titers (%) between day 0 and 21–22 months; relative reduction in median antibody titers during day 28 and 21–22 months, to poliovirus
types 1–3, by study group with 95% confidence intervals calculated using bootstrapping with 10,000 replications.
Day 0 and 21–22 months comparison Day 28 and 21–22 months comparison
Median % relative increase (95% CI) p-Value Median % relative reduction (95% CI) p-Value
Type 1 Salk IPV 1121.3 (896.4–2126.5) Ref 92.1 (84.2–92.9) Ref
Sabin IPV 1028.5 (535.1–1714.3) 0.534 92.1 (90.0–93.7) 0.543
aSabin IPV 893.0 (151.4–1904.2) 0.399 87.4 (80.1–92.1) 0.613
Type 2 Salk IPV 458.7 (147.3–1032.1) Ref 96.0 (92.9–96.8) Ref
Sabin IPV 694.7 (124.4–1305.0) 0.705 95.0 (93.7–96.0) 0.655
aSabin IPV 402.8 (100.0–893.0) 0.945 95.0 (93.7–96.8) 0.933
Type 3 Salk IPV 1043.9 (685.8–1670.5) Ref 93.7 (91.0–95.5) Ref
Sabin IPV 1276.9 (250.1–2727.8) 0.892 92.1 (91.0–95.0) 0.665
aSabin IPV 1150.0 (694.7–2396.5) 0.768 93.7 (92.1–96.8) 0.500
Note: excluded 1 subject missing data for 21–22 months.
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This study is the first to assess the decay of neutralizing anti-
bodies to Sabin poliovirus beyond 28 days after a booster dose of
Salk-IPV, Sabin-IPV, and aSabin-IPV, and found no differences
between the study groups in adults who received multiple doses
of OPV during childhood.
The only other study assessing the decay of neutralizing anti-
bodies to Sabin poliovirus beyond 28 days after vaccination, was
conducted by Okada in Japan, however this assessed antibody
titers induced in infants, 6–18 months following a primary series
administration with three doses of combination DTaP-Sabin-IPV;
the relative percentage decline in median antibody titers during
day 28 and 6–18 months was 75.3%, 63.9%, 86.3%, for poliovirus
types 1–3, respectively [8].
The greater decay for Sabin-IPV may have been due to higher
median antibody titers boosted by Sabin-IPV at day 28 with base-
line of multiple OPV doses in our study, compared to lower median
antibody titers induced by DTaP-Sabin IPV at day 28 following
primary schedule, in Okada’s study: 3565.8, 5792.6, 4096, for
Sabin-IPV in our study, compared to 2076.6, 1428.2 and 1663.5,
induced by DTaP-Sabin-IPV in Okada’s study for poliovirus types
1, 2 and 3, respectively. However, the greater decay observed
may have been an artifact, due to the differences in the dilution
of antibody titers; in our study antibody titers were diluted up to
1:65,536, however we were not able to verify the level of dilution
in Okada’s study.
Previous boosting studies for Salk-IPV demonstrated greater
antibody decay following booster dose in the developing country,
compared to industrialized country setting. A study conducted in
Oman by Sutter demonstrated a relative reduction of 72.4% inmedian antibody titers to poliovirus type 3, 6 months after admin-
istration of a booster dose of Salk-IPV, in children who received a
primary schedule of OPV. Furthermore, the decay in median anti-
body titers may have been greater in this study, as antibody titers
were only diluted up to the standard 1:1448 [15]. This contrasts
with findings from the Netherlands, published by Rumke, which
demonstrated a relative reduction in antibody geometric mean
titers of 62.1%, 71.3%, 83.5% to poliovirus types 1, 2, and 3, respec-
tively, 5 years after administration of a booster dose of DT-Salk-
IPV, in children who received a primary schedule of DTP-IPV, and
a booster dose of DT-IPV at 4 years [16,17].
Our study had some limitations. The sample size was small, lim-
ited to healthy adults from a potentially socio-economically
homogenous area. The study was conducted in a specific tropical
developing country setting. While our study found similar rates
of antibody decay in adults, at 21–22 months between Sabin-IPV,
aSabin-IPV, and Salk-IPV groups, we cannot directly extrapolate
this trend to longer term decay between the groups. Therefore sim-
ilar studies are needed to assess and compare medium and long
term antibody decay, particularly in naive children.
Our study only assessed antibodies against Sabin virus type 1, 2,
3. Previously a study conducted in infants in Poland using the same
vaccine (produced by Intravacc), demonstrated that seroconver-
sion rates against both Sabin and wild virus were equivalent
between the Sabin-IPV and Salk-IPV groups; however, neutralizing
antibody titers induced by Sabin-IPV were higher against Sabin
strains compared to wild poliovirus strains, and similarly, titers
induced by Salk-IPV were higher against wild poliovirus strains
[18]. Therefore, although we assume the rate of decay of antibodies
against Salk strains is similar between Salk and Sabin IPV, the cross
neutralisation effect is worth assessing in future studies.
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study period (10/2012–08/2014); however we concluded that sec-
ondary exposure of enrolled subjects was minimal, as although
there were four national OPV campaigns targeting children under
3 years of age, two of which also included children 9 years of age,
during this period, we did not find that any subjects demonstrated
an increase in antibody titers between day 28 and 21–22 months.
This study demonstrates comparable immunogenicity and
trends in antibody decay 21–22 months in adults who had received
multiple doses of OPV, after booster dose Sabin-IPV and aSabin-
IPV, to Salk-IPV. This should galvanize momentum for countries
and vaccine producers to further develop Sabin-IPV and aSabin-
IPV technology. Future research should be conducted to further
assess, and build the evidence for the medium and long-term
immunity of Sabin-IPV.
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